Company Number: 14225834

Analysis Date: 2025-07-20 12:05 UTC

1. Credit Opinion: CONDITIONAL APPROVAL
   Asherman Price Limited is an early-stage private limited company in management consultancy with a single director/shareholder. The latest accounts show a decline in liquidity and working capital with net current liabilities of £1,386 in 2024 compared to net current assets of £514 in 2023. While shareholders’ funds remain positive at £7,173, the significant drop in cash from £7,886 to £916 and increased current liabilities raise concerns about short-term payment capability. Conditional approval is recommended, subject to monitoring cash flow improvements and confirming sustainable revenue generation.

2. Financial Strength:
   The company holds modest fixed assets (£8,559) primarily in tangible assets such as motor vehicles and fixtures. Equity remains positive but reduced from £9,980 in 2023 to £7,173 in 2024, indicating some erosion of retained earnings or increased liabilities. The balance sheet structure shows moderate leverage, but the sharp reduction in net current assets from positive £514 to negative £1,386 is a concern. The company is classified as small with limited operational scale and a single director controlling all shares.

3. Cash Flow Assessment:
   The cash position has deteriorated markedly, with cash on hand falling from £7,886 in 2023 to £916 in 2024. Debtors increased slightly, but this does not offset the rise in current liabilities, which have dropped overall but remain high relative to current assets. Negative working capital indicates potential liquidity stress and risk of short-term funding gaps. Cash flow management and timely collection of receivables should be a focus to ensure ongoing operational liquidity.

4. Monitoring Points:

• Cash balances and working capital trends in forthcoming periods
• Debtor aging and collection efficiency
• Changes in current liabilities and creditor payment terms
• Profitability development and retained earnings trajectory
• Director’s further capital injections or external financing plans
• Compliance with filing deadlines and regulatory status